The approval introduces the first and only anti-CD20 monoclonal antibody shown to improve complete renal response in lupus nephritis, offering a new treatment option for patients and potentially delaying or preventing end-stage kidney disease.1,2,3 MISSISSAUGA, ON, Jan. 26, 2026 /CNW/ – Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 22, 2026, Health Canada has approved Gazyva® (obinutuzumab) for […]

RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results

SAN FRANCISCO–(BUSINESS WIRE)–SleepRes, Inc., a sleep technology company focused on reimagining therapy for sleep breathing disorders, today…

INCHEON, South Korea–(BUSINESS WIRE)–Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the…

WILMINGTON, Del.–(BUSINESS WIRE)–Dec. 17, 2025– Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved

EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused…

MENLO PARK, Calif.–(BUSINESS WIRE)–May Health, a medical device company dedicated to helping women living with polycystic ovary syndrome…

SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…

SHANGHAI & NEW YORK–(BUSINESS WIRE)–Shanghai Scizeng Medical Technology Co., LTD, a subsidiary of Changchun GeneScience Pharmaceutical…

LONDON & SAN FRANCISCO–(BUSINESS WIRE)–Today, Latent Labs announces Latent-X2, a frontier AI model that can design drug-like biologics..